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  The present study elucidated the effect of the selective inducible nitric oxide synthase (iNOS) 
inhibitor N
6-(1-iminoethyl)-L-lysine (L-NIL) on monosodium urate (MSU) crystal-induced inflammation 
and edema in mice feet. L-NIL (5 or 10 mg/kg/day) was administered intraperitoneally 4 h before 
injection of MSU (4 mg) into the soles of mice hindlimb feet. Twenty-four hours after MSU injection, 
foot thickness was increased by 160% and L-NIL pretreatment reduced food pad swelling in a dose 
dependent manner. Pretreatment of 10 mg/kg/day L-NIL significantly suppressed the foot pad swelling 
by MSU. Plasma level of nitric oxide (NO) metabolites and gene expression and protein level of iNOS 
in feet were increased by MSU, which was suppressed by L-NIL pretreatment. Similar pattern of 
change was observed in nitrotyrosine level. MSU increased the gene expression of tumor necrosis factor 
(TNF)-α  and interleukin (IL)-1β  and L-NIL pretreatment suppressed MSU-induced cytokines 
expression. The mRNA levels of superoxide dismutase and glutathione peroxidase1 were increased by 
MSU and L-NIL pretreatment normalized the gene expression. Phosphorylation of extracellular 
signal-regulated kinase 1/2 and p38 was increased by MSU, which was suppressed by L-NIL 
pretreatment. The mRNA levels of iNOS, TNF-α, and IL-1β were increased by MSU in human dermal 
fibroblasts, C2C12 myoblasts, and human fetal osteoblasts in vitro, which was attenuated by L-NIL 
in a dose dependent manner. This study shows that L-NIL inhibits MSU-induced inflammation and 
edema in mice feet suggesting that iNOS might be involved in MSU-induced inflammation. 
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INTRODUCTION
  Gout is caused by hyperuricemia through altered purine 
metabolism. Although asymptomatic hyperuricemia is com-
mon and the majority of patients never develop gout [1], 
gout is a common cause of arthritis affecting more than 1% 
of the adult population [2]. When the local concentration 
of uric acids exceeds the limit of solubility, monosodium ur-
ate (MSU) crystals are generated and precipitate in the 
joints, kidneys, and soft tissues, causing inflammation and 
leading to gout [3]. MSU crystals stimulate local connective 
tissue cells, monocyte-macrophages, and neutrophils to pro-
duce a variety of inflammatory cytokines including tumor 
necrosis factor (TNF)-α, interleukin (IL)-8, IL-1β, IL-6 
and monocyte chemotactic factor, which collectively induce 
acute inflammation [4,5].
  Nitric oxide (NO) is a small gas molecule synthesized by 
three isoforms of NO synthase (NOS) [6]. Although NO 
from two constitutive isoforms (endothelial NOS and neuro-
nal NOS) is critical in a wide variety of physiological func-
tions [6], overexpression of inducible NOS (iNOS) is in-
volved in a variety of pathological conditions including in-
flammation [7,8]. Although the major metabolites of NO are 
nitrite and nitrate [9], NO can be transformed to peroxyni-
trite under oxidative stress, which produces nitrated pro-
teins including nitrotyrosine [10]. Nitrotyrosine is a marker 
of peroxynitrate production and nitrative stress [11,12]. 
Expression of iNOS is also increased in MSU-stimulated 
chondrocytes and in the synovial tissue of gouty arthritis 
patients, suggesting a potential role of iNOS in the patho-
genesis of arthritis [13,14]. However, no direct evidence of 
the involvement of iNOS in gout has been reported. In this 
study, the role of iNOS in gouty arthritis was elucidated 
by examining whether a selective iNOS inhibitor sup-
pressed MSU-induced inflammation in a mouse foot model.364 TJ Ju, et al
METHODS
Animals
  Seven-week-old male C57BL/6 mice were housed in a 
room operating with a 12:12 h light/dark cycle. All the mice 
were fed a standard chow diet with free access to water. 
For the preparation of MSU crystals, 4 g of uric acid was 
dissolved at 60
oC in 800 ml of 0.5 M NaOH (pH 8) and 
cooled overnight at 4
oC. After discarding the supernatant, 
precipitated crystals were collected, washed and dried. The 
needle-like crystals were dissolved in saline (0.04 g/500μl) 
and 4 mg/50μl of the solution was injected into soles of 
hindlimb feet of the mice [15]. This concentration is high 
enough to induce inflammation since the solubility of uric 
acid in plasma is 6.8 mg/dl [16]. The iNOS selective in-
hibitor N
6-(1-iminoethyl)-L-lysine (L-NIL; Cayman Chemi-
cal, Ann Arbor, MI, USA)[17,18] was injected into mice in-
traperitoneally (10 mg/kg) 4 h before MSU injection. 
Twenty four hours after MSU injection, edema of feet was 
measured using digital calipers (Mitutoyo Corporation, 
Kawasaki-shi, Kanagawa, Japan) in mice anesthetized with 
an intraperitoneal injection of tiletamine and zolezepam (25 
mg/kg) and zylazine (10 mg/kg). Blood was collected from 
the retro-orbital plexus using micro-hematocrit capillary 
tubes coated with heparin. The blood was centrifuged and 
plasma was stored at −80
oC for further analysis. The feet 
were excised and stored at −80
oC for further analysis. This 
study was conducted in accordance with the guidelines for 
the care and use of laboratory animals provided by 
Yeungnam University, and all experimental protocols were 
approved by the Ethics Committee of Yeungnam Uni-
versity.
Cell culture
    Human dermal fibroblast (HDF) was purchase from 
Lonza (Walkersville, MS, USA) and mouse myoblast cell 
line, C2C12, and human fetal osteoblastic cell line, 
hFOB1.19, were purchased from the American Type Cul-
ture Collection (Manassas, VA, USA). HDF and C2C12 
were culture in Dulbecco’s Modified Eagle Media (DMEM; 
GIBCO, Grand Island, NY, USA) at 37
oC in a 5% 
CO2-humidifier incubator. hFOB1.19 cells were cultured in 
a 1：1 mixture of DMEM and F12 (GIBCO) without phenol 
red at 36.5
oC in an atmosphere containing 5% CO2. The 
cells were plated at 1×10
6 to each of 6 wells and treated 
with 2 mg MSU for 2 h. L-NIL (0.25 or 0.5 mg/ml) was 
added into the cells 30 min before MSU treatment. RNA 
extraction was performed for the quantitative real time pol-
ymerase chain reaction (qRT-PCR).
qRT-PCR
  qRT-PCT was performed as previously described [19]. 
Briefly, 25 mg tissue samples were homogenized in TRI re-
agent (Sigma-Aldrich, St. Louis, MO, USA) and RNA was 
reverse transcribed to cDNA using a reverse transcription 
kit (Applied Biosystems, Foster City, CA, USA). Quantita-
tive real-time PCR was performed using the Real-Time 
PCR 7500 System and Power SYBR Green PCR Master Mix 
(Applied Biosystems) according to the manufacturer's 
instructions. Expression levels of β-actin were used for 
sample normalization. Each reaction mixture was in-
cubated at 95
oC for 10 min followed by 45 cycles of 95
oC 
for 15 s, 55
oC for 20 s and 72
oC for 35 s. Sequences of pri-
mers were based on the National Center for Biotechnology 
Information nucleotide database and were designed using 
the Primer Express Program (Applied Biosystems). The pri-
mer sequences were: mouse β-actin (121 bp: forward, 
5'-TGG ACA GTG AGG CAA GGA TAG-3'; reverse, 5'-TAC 
TGC CCT GGC TCC TAG CA-3'), mouse iNOS (71 bp: for-
ward, 5'-CTC CTG CCT CAT GCC ATT-3'; reverse, 5'-TGT 
TCC TCT ATT TTT GCC TCT TTA-3'), mouse TNF-α (71 
bp: forward, 5'-CTA TCT CCA GGT TCT CTT CAA-3'; re-
verse, 5'-GCA GAG AGG AGG TTG ACT TTC), mouse IL-1β 
(71 bp: forward, 5'-GCC CAT CCT CTG TGA CTC-A-3'; re-
verse, 5'-AGT GCA GCT GTC TAA TGG GA-3'), mouse su-
peroxide dismutase (SOD; 71 bp: forward, 5'-CTG CTC TAA 
TCA GGA CCC ATT-3'; reverse, 5'-GTG CTC CCA CAC 
GTC AAT C-3'), mouse glutathione peroxidase 1 (GPx1; 71 
bp: forward, 5'-GAA GTG CGA AGT GAA TGG TG-3'; re-
verse, 5'-TGG GTG TTG GCA AGG C-3'), human β-actin 
(72 bp: forward, 5'-ACC GCA TCG TCA CCA AC-3'; reverse, 
5'-CCA CAC GCA GCT CAT TGT A-3'), human iNOS (192 
bp:forward, 5'-TTA TGA CTC CCA AAA GTT TGA CCA-3'; 
reverse, 5'-CCG TCA GTT GGT AGG TTA CTG TTG-3'), 
human TNF-α (72 bp: forward, 5'-AGA GGG CCT GTA 
CCT CAT CTA-3'; reverse, 5'-AGC AGC ACA TGG GTC 
GAG-3'), and IL-1β (133 bp: forward, 5'-TCC AGG GAC 
AGG ATA TGG AG-3'; reverse, 5'-TCT TTC AAC ACG CAG 
GAC AG-3').
Western blotting
  Foot samples were used for measurement of the protein 
level of phosphorylated extracellular signal-related kinase 
(pERK; Cell Signaling Technologies, Danvers, MA, USA), 
ERK (Cell Signaling Technologies), p38 (Cell Signaling 
Technologies), p-p38 (Cell Signaling Technologies), iNOS 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), nitro-
tyrosine (Upstate Biotechnology, Lake Placid, NY, USA), 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 
Santa Cruz Biotechnology). Western blotting was per-
formed as previously described [12]. Briefly, 25 mg tissue 
samples were homogenized in lysis buffer (Invitrogen, 
Carlsbad, CA, USA) and extracted protein was separated 
by 10% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). Resolved proteins were transferred 
to a polyvinylidene fluoride membrane (Millipore, Billerica, 
MA, USA). After blocking with 5% skim mile, the mem-
brane was incubated overnight at 4
oC with primary anti-
body and then specific antibody binding was detected using 
sheep anti-rabbit IgG horseradish peroxidase or goat an-
ti-mouse IgG horseradish peroxidase (Bio-Rad, Hercules, 
CA, USA) for 1 h at room temperature, except for nitro-
tyrosine, which was detected using mouse anti-mouse IgG 
horseradish peroxidase (Bio-Rad). The binding was vi-
sualized using an enhanced chemiluminescence detection 
regent (Millipore).
Nitrite and nitrate
  Plasma concentrations of the NO-derived end products 
nitrite and nitrate were measured by a TotalNOAssay Kit 
(R&D Systems, Minneapolis, MN, USA). To minimize inter-
ference with plasma protein, the sample was ultra-filtered 
through a 10 kDa cut-off filter (Millipore) prior to the assay.iNOS in MSU-induced Inflammation 365
Fig. 1. Thickness of feet in mice injected with monosodium-urate 
(MSU) into hindlimb feet sole. N
6-(1-iminoethyl)-L-lysine (L-NIL; 
5 and 10 mg/kg) was injected intraperitoneally 4 h before MSU 
( 4  m g )  i n j e c t i o n .  D a t a  i s  p r e s e n t e d  a s  m e a n ± S E .  E x p e r i m e n t a l  
cases are seven in each group. *p＜0.05 vs. Saline, 
#p＜0.05 vs. 
MSU.
Fig. 2. Nitric oxide metabolites in 
plasma (A) and the expression of 
inducible nitric oxide synthase (iNOS;
B, C) and nitrotyrosine (D) in the 
feet of mice injected with monoso-
dium-urate (MSU) into hindlimb 
sole. N
6-(1-iminoethyl)-L-lysine (L- 
NIL; 10 mg/kg) was injected intra-
peritoneally 4 h before MSU (4 mg) 
injection. Data is presented as mean 
±SE. Experimental cases are seven 
in each group. *p＜0.05 vs. Saline, 
#p
＜0.05 vs. MSU.
Statistical analysis
  Data are expressed as mean ± standard error (SE). The 
difference among groups was analyzed by ANOVA with a 
post-hoc analysis by Duncan’s multiple test. Statistical sig-
nificance was at p＜0.05.
RESULTS
Feet edema
  MSU injection into the soles induced redness, swelling, 
and heat in mice feet (data not shown) and significantly 
increased the thickness of feet by 160% at 24 h compared 
with the saline injected feet. Pretreatment of 5 and 10 
mg/kg L-NIL suppressed MSU-induced edema by 12% and 
40%, respectively, while L-NIL alone had no effect on the 
thickness of feet (Fig. 1). Since 10 mg/kg/day L-NIL sig-
nificantly reduced MSU-induced foot pad swelling, this con-
centration of L-NIL was used in this experiment.
iNOS expression
  Plasma levels of the NO metabolites nitrite and nitrate 
was reduced by L-NIL administration compared with 
control. MSU injection increased the NO metabolites in 
plasma, which was reversed by L-NIL pretreatment (Fig. 
2A). While gene expression of iNOS was not affected by 
L-NIL, the mRNA level of iNOS in feet was significantly 
increased by MSU. L-NIL pretreatment suppressed MSU- 
induced gene expression of iNOS (Fig. 2B). Protein level 
of iNOS in feet showed the same pattern of changes as with 
iNOS gene expression, except that L-NIL treatment alone 
significantly reduced the level of iNOS protein (Fig. 2C). 
Nitrotyrosine level in feet was significantly increased by 
MSU injection, which was partially suppressed by L-NIL 
pretreatment. Like the iNOS protein level, nitrotyrosine 
was significantly reduced by L-NIL treatment (Fig. 2D).
Gene expression of inflammatory cytokines and anti-
oxidant enzyme
  Gene expression of TNF-α was also increased by MSU, 
which was significantly reduced by L-NIL pretreatment. 
However, MSU-induced TNF-α expression was not com-
pletely normalized by L-NIL pretreatment compared with 
saline-injected control mice. L-NIL treatment did not alter 
the mRNA level of TNF-α. While L-NIL had no effect on 
the gene expression of IL-β, the mRNA level of IL-1β was 
significantly increased by MSU. L-NIL pretreatment sup-366 TJ Ju, et al
Fig. 3. The mRNA level of inflam-
matory cytokines and antioxidant 
enzymes in the foot of mice injected 
with monosodium-urate (MSU) into 
hindlimb sole. N
6-(1-iminoethyl)-L- 
lysine (L-NIL; 10 mg/kg) was in-
jected intraperitoneally 4 h before 
MSU (4 mg) injection. Interleukin 
(IL)-1β (A); tumor necrosis factor 
(TNF)-α (B); glutathione peroxidase 
(GPx) 1 (C); superoxide dismutase 
(SOD) (D). Data is presented as 
mean±SE. Experimental cases are 
seven in each group. *p＜0.05 vs. 
Saline, 
#p＜0.05 vs. MSU.
Fig. 4. The phosphorylation of extra-
cellular signal-related kinase (ERK) 
1/2 (A) and p38 (B) in the foot of mice 
injected with monosodium-urate 
(MSU) into hindlimb sole. N
6-(1-imi-
noethyl)- L-lysine (L-NIL; 10 mg/kg) 
was injected intraperitoneally 4 h 
before MSU (4 mg) injection. Data is 
presented as mean±SE. Experimen-
tal cases are seven in each group. *p
＜0.05 vs. Saline, 
#p＜0.05 vs. MSU.
pressed MSU-induced gene expression of IL-1β. MSU also 
elevated the mRNA level of GPX1 and SOD and L-NIL pre-
treatment suppressed MSU-induced the gene expression of 
these antioxidants enzymes (Fig. 3).
Mitogen-activated protein kinase (MAPK) expression
  Phosphorylation of ERK1/2 and p38 was increased by 
MSU, which was reversed by L-NIL pretreatment. L-NIL 
alone did not alter the phosphorylation of ERK1/2 and p38 
(Fig. 4). Phosphorylation of c-Jun-N-terminal kinase (JNK) 
was not affected by either MSU or L-NIL (data not shown). 
Gene expression of iNOS and cytokines in cell lines
  Gene expression of iNOS was increased in HDF, C2C12, 
and hFOB1.19 by MSU and L-NIL pretreatment attenu-
ated iNOS mRNA expression in a dose dependent manner. 
Gene expression of iNOS was reduced by L-NIL treatment 
alone. MSU also increased mRNA expression of TNF-α and 
IL-1β in HDF, C2C12, and hFOB1.19, which were sig-
nificantly attenuated by L-NIL in a dose dependent manner 
(Fig. 5).
DISCUSSION
  The present study demonstrates that MSU induces ede-
ma and increases inflammatory cytokine expression in feet 
that is accompanied with increased iNOS expression. The 
selective iNOS inhibitor L-NIL suppresses the edema and 
cytokine expression. These results suggest that iNOS is in-
volved in the development of gout.
  The association between iNOS and rheumatoid arthritis 
or/and osteoarthritis has been extensively investigated and 
a large body of evidence suggests the important role of 
iNOS in these arthritis. The expression of iNOS is in-
creased in the synovium, chondrocytes, vascular smooth 
muscle and inflammatory cells of rheumatoid arthritis and 
osteoarthritis subjects [20-24]. Moreover, suppression of iNOS in MSU-induced Inflammation 367
Fig. 5. The mRNA level of iNOS, tumor necrosis factor (TNF)-α, and interleukin (IL)-1β in human dermal fibroblast (HDF; A∼C), C2C12 
myoblast, and (D∼F) human fetal osteoblast (hFOB)1.19 (G∼I). The cells were treated with 2 mg/ml monosodium-urate (MSU) for 2 h. 
N
6-(1-iminoethyl)-L-lysine (L-NIL) was treated into cells 30 min before MSU treatment. Data is presented as mean±SE of three separate 
experiments. *p＜0.05 vs. Control, 
#p＜0.05 vs. MSU, 
&p＜0.05 vs. 0.25 mg/ml L-NIL.
iNOS expression in rheumatoid arthritis and osteoarthritis 
attenuates cell apoptosis, cytokine production and arthritis 
[20,25-27].
  Despite extensive investigations as to the role of iNOS 
in rheumatoid arthritis and osteoarthritis, the relationship 
between iNOS and gouty arthritis has not been well- 
defined. Previous research has indicated that MSU in-
creases iNOS expression in cells such as macrophages and 
chondrocytes in vitro [13,14,28]. Similar to this finding, we 
presently showed that MSU increased iNOS expression in 
fibroblast, myoblast, and osteoblast in vitro. Furthermore, 
we also observed that iNOS expression was increased in 
mice feet by MSU treatment, which is the first study show-
ing increased iNOS expression by MSU treatment in vivo. 
The elevated levels of NO metabolites in plasma indirectly 
support increased iNOS expression by MSU. Additionally, 
the suppression of MSU-induced iNOS expression by L-NIL 
resulted in attenuated cytokine expression and edema. 
Consistent with our results, iNOS expression is enhanced 
in synovial tissues of gouty arthritis patients [13]. Together 
with this previous data, the current results support the no-
tion that increased iNOS expression plays a causative role 
in the inflammation induced by MSU.
  The mechanism by which MSU induces iNOS expression 
is unclear presently, but it is possible that MSU increases 
iNOS expression through MAPK pathways. MSU increases 
the MAPK subfamily member JNK, p38, and ERK1/2 
[13,29,30], which are involved in a variety of MSU-induced 
pathological pathways [31]. ERK1/2 is involved in MSU- 
mediated transcriptional activation of IL-8 that functions 
as a neutrophil chemoattractant factor [29]. Inhibition of 
ERK1/2 or p38 reduces MSU-induced monocyte chemo-
attractant protein-1 in vascular smooth muscle cells [32]. 
MSU-induced iNOS expression is also mediated by p38 and 
ERK1/2 in chondrocytes and macrophages [13,14,28]. MSU 
activates p38 through the phosphorylation of proline-rich 
tyrosine kinase 2/focal adhesion kinase/protein paxillin, 
which increases iNOS expression and NO production [14]. 
Inhibition of ERK1/2 by specific inhibitor suppresses MSU- 
induced iNOS expression [13,28]. Consistent with these 
previous results, we presently observed that MSU in-
creased the phosphorylation of ERK1/2 and p38. Addition-
ally, the suppression of MSU-induced iNOS expression by 
L-NIL was accompanied with decreased the phosphor-
ylation of both ERK1/2 and p38. Taken together, these re-
sults suggest the involvement of ERK/12 or/and p38 in 
MSU-induced iNOS expression. Although JNK is also in-
creased in human monocyte cells line by MSU [33], JNK 
was not presently increased by MSU. Difference of species 
and experimental conditions could be the possible reasons. 
  We assume that increased iNOS expression could acti-
vate the production of inflammatory cytokines, which sub-368 TJ Ju, et al
sequently play a key role in gouty arthritis. Our notion is 
supported by the observation that suppression of MSU-in-
duced iNOS expression by L-NIL presently attenuated cyto-
kine expression and edema. A Previous study also demon-
strated that the NO donor S-nitroso-acetyl penicillamine in-
creases inflammatory cytokines such as TNF-α [34]. Gouty 
arthritis and administration of MSU crystal results in the 
production of a variety of inflammatory cytokines [35-37] 
and increased expressions of anti-inflammatory cytokines 
such as transforming growth factor β1, IL-1 receptor an-
tagonist, IL-10, and soluble TNF receptor are correlated 
with spontaneous resolution of gouty arthritis [38].
  Gouty arthritis is associated with oxidative stress [39] 
and the suppression of oxidative stress can reduce the 
symptoms [40]. Oxidative stress in gout may involve MSU- 
induced iNOS expression since elevated NO production 
from iNOS induces oxidative stress [12]. Presently, MSU 
increased the gene expression of anti-oxidant enzymes, 
which was normalized by L-NIL treatment. Antioxidant en-
zyme may be increased to protect the tissue from oxidative 
damage and attenuated oxidative stress by L-NIL normal-
izes the enzyme levels. Increased nitrotyrosine level by 
MSU was attenuated by L-NIL treatment presently, which 
also supports our theory.
  In summary, MSU induces iNOS expression that is asso-
ciated with increased expression of inflammatory cytokines, 
oxidative stress, and edema. ERK1/2 or/and p38 may medi-
ates MSU-induced iNOS expression. Suppression of iNOS 
could be a new therapeutic target for gout.
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